期刊文献+

氪红激光早期光凝治疗视网膜分支静脉阻塞的疗效评估 被引量:3

Treatment efficacy of krypton-red laser on early stage of branch retinal vein occlusion
下载PDF
导出
摘要 目的 对视网膜分支静脉阻塞视网膜光凝术的早期与晚期治疗进行疗效评估。 方法 将88例视网膜分支静脉阻塞患者分为3个月内光凝治疗早期组和3个月后光凝治疗晚期组。2组病例均配合常规的药物治疗,光凝后随访6~18个月,观察2组治疗后视力、荧光素眼底血管造影(FFA)检查及光学相干断层扫描(OCT)图像分析。 结果 早期组视力恢复至0.6以上者26例,占56.5%,9例恢复至1.0以上,无1例<0.1者。晚期治疗组视力<0.1者达10例,视力恢复至0.6以上者11例,占26.1%。2组随诊结果显示,甲期治疗组视力显效明显优于晚期治疗组. 结论 早期治疗组效果明显优于晚期治疗组。视网膜静脉阻塞应采取早期激光治疗,以促使视网膜出血、渗出、水肿尽快吸收,这对于改善视力预后有重要意义。 Objective To compare the effect of krypton-red laser on branch retinal vein occlusion in the early stage and for the extended period. Methods Eighty-eight cases with branch retinal vein occlusion were divided into the early and the extended treating group. They were treated with the krypton-red laser at different time. The changes of fundus, fundus fluorescein angiography( FFA) and optical coherence tomography ( OCT) were analyzed following laser treatment. All of the eyes were followed up for 6 - 18 months. Results The visual acuity of photocoagulative cases in the early stage got significantly improved as compared with the extented group. Conclusion The treating efficacy in early stage cases are better than that of the longer period ones. The branch retinal vein occlusion should be treated as early as possible .
作者 戴奕娟
机构地区 唐山市眼科医院
出处 《眼科研究》 CSCD 北大核心 2003年第1期59-61,共3页 Chinese Ophthalmic Research
关键词 氪红激光 早期 视网膜分支静脉阻塞 疗效 晚期 激光凝固术 branch retinal vein occlusion krypton-red laser laser photocoagulation
  • 相关文献

参考文献1

  • 1张惠蓉.视网膜病临床和基础研究[M].山西:山西科学技术出版社,1999.290-291.

共引文献8

同被引文献38

  • 1王海波,赵晓辉,邢怡桥.玻璃体内注射曲安奈德治疗黄斑水肿的临床观察[J].中华眼底病杂志,2005,21(5):326-327. 被引量:5
  • 2原艳波,王康孙,张明珩,廉井财,石海云.倍频Nd:YAG(532)固体激光器治疗视网膜分支静脉阻塞的疗效评价[J].中国实用眼科杂志,1996,14(8):480-482. 被引量:7
  • 3毛新帮,赵菊莲,游志鹏.视网膜血管阻塞性疾病的治疗进展[J].中国实用眼科杂志,2006,24(12):1240-1243. 被引量:11
  • 4钱彤,黎晓新.玻璃体腔注射曲安奈德后的眼压改变[J].中华眼底病杂志,2007,23(2):115-117. 被引量:35
  • 5Russo V,Barone A, Conte E,Prascina F,Stella A,Noci ND. Bevacizumab compared with macular laser grid photocoagulation for cystoid macular edema in branch retinal vein occlusion[ J]. Retina,2009,29(4) :511-515.
  • 6Pece A,Isola V, Piermarocchi S, Calori G. Efficacy and safety of anti-vascular endothelial growth factor (VEGF) therapy with intravitreal ranibizumab (Lucentis) for naive retinal vein occlusion: 1-year follow-up [ J ], Br J Ophthalmol, 2011,95 ( 1 ) :55-58.
  • 7Rouvas A,Petrou P, Ntouraki A, Douvali M, Ladas I, Vergados I. Intravitreal ranibizumab (Lucentis) for branch retinal vein occlusion-induced macular edema:nine-month results of a prospective study[ J]. Retina,2010,30(6) :893-902.
  • 8Mason JO 3rd,Frederick PA,Neimkin MG,White MF,Feist RM, Thomley ML,et al. Incidence of hemorrhagic complications after intravitreal bevacizumab (avastin) or ranibizumab (lucentis) injections on systemically anticoagulated patients [ J ]. Retina, 30 (9) :1386-1389.
  • 9Nguyen QD, Shah SM,Hafiz G, Quinlan E, Sung J, Chu K, et al. A phase I trial of an W-administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration[ J ]. Ophthalmology,2006,113 (9) :1522. e1-1522, e14.
  • 10Raftery J, Clegg A, Jones J, Tan SC, Lotery A. Ranibizumab ( Lucentis) versus bevacizumab ( Avastin ) : modelling cost effectiveness[J]. Br J Ophthalmol,2007,91 (9) :1244-1245.

引证文献3

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部